Bladder cancer and its signs and symptoms
Our understanding of the molecular mechanisms of tumour development and how tumours spread has continually improved, leading to major breakthroughs that have transformed several aspects of cancer care. Roche’s scientists are pioneers in cancer research, and they continuously investigate innovative and personalised treatment options.
Explore the latest in Roche's research and developments in oncology.
The randomised, double-blind, Phase III APHINITY study compared ▼pertuzumab, trastuzumab, + chemotherapy with placebo, trastuzumab, + chemotherapy in the adjuvant HER2-positive early breast cancer setting. This presentation describes the second interim analysis of overall survival, along with updated invasive disease-free survival and safety data.
GO29831 is a multi-cohort Phase Ib study evaluating the safety and tolerability of ▼atezolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer and locally advanced early breast cancer, and ▼atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer. We report the safety and biomarker outcomes from this study.
IMpassion130 is a global, Phase III study evaluating ▼atezolizumab + nab-paclitaxel versus placebo + nab-paclitaxel as a first-line treatment in patients with metastatic triple-negative breast cancer. In this retrospective analysis of IMpassion130, we used modeling to explore different cutoff values that could potentially harmonize the 22C3 and SP263 PD-L1 IHC assays with the reference standard assay SP142 at cutoff IC 1%.
A drug- and indication-specific module for the Kaiku digital patient monitoring (DPM) platform was co-developed with patients and healthcare professionals (HCPs) for cancer immunotherapy-treated patients with advanced/metastatic non-small cell lung cancer. A pilot study was conducted to assess user experience, overall satisfaction and the impact of the DPM tool on clinical care. This poster reports results from patient and HCP surveys, as well as HCP interviews, over a minimum of three months of DPM tool use.
This retrospective observational study evaluated the association of baseline corticosteroid use with overall survival in patients receiving cancer immunotherapy for advanced or metastatic melanoma, non-small cell lung cancer or urothelial carcinoma in US clinical practice.
IMpower110 is a randomized, Phase III study of atezolizumab monotherapy vs platinum-based chemotherapy in PD-L1–selected, chemo-naive patients with metastatic NSCLC. Efficacy analyses in key pre-specified subgroups in IMpower110, defined by the 22C3 and SP263 PD-L1 IHC and bTMB assays are reported
This poster describes the safety and preliminary efficacy of first-line atezolizumab monotherapy in a cohort of patients with locally advanced or metastatic melanoma whose tumors had wild-type BRAF at codon 600. In addition to safety, this reports the objective response rate, duration of response and progression-free survival for these patients (Cohort C of CO39721: NCT03178851).
This poster describes real world treatment patterns for CNS metastases and survival outcomes in melanoma patients with metastatic disease using data from the Flatiron Health database
This final report of the of the phase 3 coBRIM study reports the safety and clinical benefit of cobimetinib plus vemurafenib versus vemurafenib alone in patients with advanced BRAFV600-mutated melanoma after an extended follow-up.
Here we report the randomised dataset evaluating ▼atezolizumab (anti-PD-L1) as monotherapy vs the combination of ▼atezolizumab + bevacizumab (anti-VEGF; Arm F) as well as updated single-arm ▼atezolizumab + bevacizumab data (Arm A) from a Phase 1b study in patients with previously untreated, unresectable hepatocellular carcinoma.
Entrectinib is an oral, CNS-active, potent and selective inhibitor of kinases encoded by ROS1, NTRK and ALK genes. It was specifically designed to cross the blood–brain barrier and remain within the CNS and is a more potent ROS1 inhibitor than crizotinib. This is an analysis of the incidence of brain metastases and the treatment patterns of patients with ROS1-positive NSCLC.
Entrectinib is a potent and selective ROS1/NTRK/ALK tyrosine kinase inhibitor. This is an update to the integrated analysis from three Phase 1/2 entrectinib trials for adults with NTRK fusion-positive solid tumors after an additional 5 months of follow-up.
Entrectinib is an oral, potent and selective ROS1/NTRK/ALK tyrosine kinase inhibitor designed to cross the blood–brain barrier and remain within the CNS. This is an integrated efficacy and safety analysis of three studies of entrectinib focusing on a cohort of patients (n=6) with NTRK fusion-positive sarcoma.